176 related articles for article (PubMed ID: 29066764)
1. Aberrant glioblastoma neovascularization patterns and their correlation with DCE-MRI-derived parameters following temozolomide and bevacizumab treatment.
Xue W; Du X; Wu H; Liu H; Xie T; Tong H; Chen X; Guo Y; Zhang W
Sci Rep; 2017 Oct; 7(1):13894. PubMed ID: 29066764
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
3. Amino acid PET tracers are reliable markers of treatment responses to single-agent or combination therapies including temozolomide, interferon-β, and/or bevacizumab for glioblastoma.
Ono T; Sasajima T; Doi Y; Oka S; Ono M; Kanagawa M; Baden A; Mizoi K; Shimizu H
Nucl Med Biol; 2015 Jul; 42(7):598-607. PubMed ID: 25892210
[TBL] [Abstract][Full Text] [Related]
4. [
Provost C; Rozenblum-Beddok L; Nataf V; Merabtene F; Prignon A; Talbot JN
Mol Imaging Biol; 2019 Apr; 21(2):297-305. PubMed ID: 29948641
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
O'Halloran PJ; Viel T; Murray DW; Wachsmuth L; Schwegmann K; Wagner S; Kopka K; Jarzabek MA; Dicker P; Hermann S; Faber C; Klasen T; Schäfers M; O'Brien D; Prehn JH; Jacobs AH; Byrne AT
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1673-83. PubMed ID: 26975402
[TBL] [Abstract][Full Text] [Related]
6. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.
Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V
Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study.
Zhu P; Du XL; Lu G; Zhu JJ
Oncotarget; 2017 Jul; 8(27):44015-44031. PubMed ID: 28467795
[TBL] [Abstract][Full Text] [Related]
8. Combining dynamic contrast enhanced magnetic resonance imaging and microvessel density to assess the angiogenesis after PEI in a rabbit VX2 liver tumor model.
Chen J; Qian T; Zhang H; Wei C; Meng F; Yin H
Magn Reson Imaging; 2016 Feb; 34(2):177-82. PubMed ID: 26518059
[TBL] [Abstract][Full Text] [Related]
9. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).
Reyes-Botero G; Cartalat-Carel S; Chinot OL; Barrie M; Taillandier L; Beauchesne P; Catry-Thomas I; Barrière J; Guillamo JS; Fabbro M; Frappaz D; Benouaich-Amiel A; Le Rhun E; Campello C; Tennevet I; Ghiringhelli F; Tanguy ML; Mokhtari K; Honnorat J; Delattre JY
Oncologist; 2018 May; 23(5):524-e44. PubMed ID: 29472310
[TBL] [Abstract][Full Text] [Related]
14. Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.
Consolino L; Longo DL; Sciortino M; Dastrù W; Cabodi S; Giovenzana GB; Aime S
Gastric Cancer; 2017 Jul; 20(4):629-639. PubMed ID: 27995483
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of neovascularization patterns in an orthotopic rat glioma model with dynamic contrast-enhanced MRI.
Xuesong D; Wei X; Heng L; Xiao C; Shunan W; Yu G; Weiguo Z
Acta Radiol; 2017 Sep; 58(9):1138-1146. PubMed ID: 27956462
[TBL] [Abstract][Full Text] [Related]
16. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
[TBL] [Abstract][Full Text] [Related]
17. MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Beppu T; Terasaki K; Sasaki T; Sato Y; Tomabechi M; Kato K; Sasaki M; Ogasawara K
Clin Nucl Med; 2016 Nov; 41(11):852-857. PubMed ID: 27648703
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
[TBL] [Abstract][Full Text] [Related]
19. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.
Tanaka T; Tamura R; Takei J; Morimoto Y; Teshigawara A; Yamamoto Y; Imai R; Kuranari Y; Tohmoto K; Hasegawa Y; Akasaki Y; Murayama Y; Miyake K; Sasaki H
J Neurooncol; 2024 Feb; 166(3):557-567. PubMed ID: 38291182
[TBL] [Abstract][Full Text] [Related]
20. Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma.
Adilijiang A; Hirano M; Okuno Y; Aoki K; Ohka F; Maeda S; Tanahashi K; Motomura K; Shimizu H; Yamaguchi J; Wakabayashi T; Natsume A
Molecules; 2019 Aug; 24(17):. PubMed ID: 31443404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
